全文获取类型
收费全文 | 63457篇 |
免费 | 4553篇 |
国内免费 | 1895篇 |
专业分类
耳鼻咽喉 | 407篇 |
儿科学 | 1049篇 |
妇产科学 | 711篇 |
基础医学 | 5090篇 |
口腔科学 | 1093篇 |
临床医学 | 5708篇 |
内科学 | 6360篇 |
皮肤病学 | 532篇 |
神经病学 | 3320篇 |
特种医学 | 1514篇 |
外国民族医学 | 6篇 |
外科学 | 5941篇 |
综合类 | 12180篇 |
现状与发展 | 2篇 |
一般理论 | 5篇 |
预防医学 | 5406篇 |
眼科学 | 963篇 |
药学 | 6587篇 |
115篇 | |
中国医学 | 11112篇 |
肿瘤学 | 1804篇 |
出版年
2024年 | 172篇 |
2023年 | 1112篇 |
2022年 | 1805篇 |
2021年 | 2727篇 |
2020年 | 2546篇 |
2019年 | 2550篇 |
2018年 | 2215篇 |
2017年 | 2167篇 |
2016年 | 2069篇 |
2015年 | 1813篇 |
2014年 | 4224篇 |
2013年 | 3774篇 |
2012年 | 3752篇 |
2011年 | 4523篇 |
2010年 | 4065篇 |
2009年 | 3012篇 |
2008年 | 2779篇 |
2007年 | 2981篇 |
2006年 | 2731篇 |
2005年 | 2319篇 |
2004年 | 1863篇 |
2003年 | 1744篇 |
2002年 | 1247篇 |
2001年 | 1122篇 |
2000年 | 885篇 |
1999年 | 818篇 |
1998年 | 641篇 |
1997年 | 616篇 |
1996年 | 491篇 |
1995年 | 545篇 |
1994年 | 523篇 |
1993年 | 385篇 |
1992年 | 385篇 |
1991年 | 328篇 |
1990年 | 278篇 |
1989年 | 264篇 |
1988年 | 275篇 |
1987年 | 215篇 |
1986年 | 213篇 |
1985年 | 435篇 |
1984年 | 425篇 |
1983年 | 336篇 |
1982年 | 369篇 |
1981年 | 370篇 |
1980年 | 351篇 |
1979年 | 320篇 |
1978年 | 275篇 |
1977年 | 250篇 |
1976年 | 186篇 |
1975年 | 113篇 |
排序方式: 共有10000条查询结果,搜索用时 218 毫秒
1.
熊磊教授以理脾为本,将治痰贯穿始终。根据小儿脾常不足、肾常虚、肝常有余的生理特点,癫痫发作期治疗主以涤痰开窍,辅以理气健脾,同时配合活血化瘀通窍与平肝息风潜阳。主要选方为柴芍温胆汤、天麻钩藤饮、桃红四物汤加减;缓解期则以补肾养肝为主,兼以健脾化痰,主要选方为杞菊地黄丸合定痫丸加减,取得较好临床疗效。 相似文献
2.
中医学古籍中罕有关于“胰腺”的明确记载,缺乏直观、系统的理论论述。本文试图通过对各个时期具有代表性的医学典籍所记载内容的分析,结合现代解剖学相关理论,梳理中医学对胰腺实体解剖的认识过程。通过分析,笔者认为中医学对胰腺实体解剖的认识具有阶段性:①先秦两汉时期,存在胰腺实体解剖,但并非认为胰腺是脏器;②唐宋时期,胰腺实体解剖更加清晰,在医学上胰腺附属于脾,并非为独立的脏器;③明清时期,胰腺实体解剖明确,部分医家以独立脏器论之,出现“脾”、“胰”之争。中医学理论缺少对胰腺的单独论述,目前学界的主流观点多为“胰属脾”,线性归属以脾笼统代之略显单薄,不利于理论的丰富与发展。笔者认为胰腺藏象应独立于脾单独讨论,现代解剖学对胰腺命名同一,形态结构清楚,位置描述明确,可直接补充进中医学胰腺藏象(藏)理论中,为完善胰腺藏象理论搭建解剖学基础。 相似文献
3.
4.
5.
6.
7.
《Journal of vascular and interventional radiology : JVIR》2022,33(4):359-367.e8
PurposeTo review and to compare indirectly the outcomes of minimally invasive therapies for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia.Materials and MethodsA literature search via Medline and Cochrane Central databases was completed for randomized control studies published between January 2000 to April 2020 for the following therapies: Rezum, Urolift, Aquablation, and prostatic artery embolization (PAE). Data on the following variables were included: International prostate symptom score (IPSS), maximum urinary flow rate, quality of life, and postvoid residual (PVR). Standard mean differences between treatments were compared through a meta-analysis using transurethral resection of the prostate (TURP) to assess differences in treatment effect.ResultsThere was no significant difference in outcomes between therapies for IPSS at the 3, 6, and 12-month follow ups. Although outcomes for Rezum were only available out to 3 months, there were no consistently significant differences in outcomes when comparing Aquablation versus PAE versus Rezum. TURP PVR was significantly better than Urolift at 3, 6, and 12 months. No significant differences in minor or major adverse events were noted.ConclusionAlthough significant differences in outcomes were limited, Aquablation and PAE were the most durable at 12 months. PAE has been well studied on multiple randomized control trials with minimal adverse events while Aquablation has limited high quality data and has been associated with bleeding-related complications. 相似文献
8.
《Journal of pediatric surgery》2023,58(5):856-861
Background/PurposeA small number of Hirschsprung disease (HD) patients develop inflammatory bowel disease (IBD)-like symptoms after pullthrough surgery. The etiology and pathophysiology of Hirschsprung-associated IBD (HD-IBD) remains unknown. This study aims to further characterize HD-IBD, to identify potential risk factors and to evaluate response to treatment in a large group of patients.MethodsRetrospective study of patients diagnosed with IBD after pullthrough surgery between 2000 and 2021 at 17 institutions. Data regarding clinical presentation and course of HD and IBD were reviewed. Effectiveness of medical therapy for IBD was recorded using a Likert scale.ResultsThere were 55 patients (78% male). 50% (n = 28) had long segment disease. Hirschsprung-associated enterocolitis (HAEC) was reported in 68% (n = 36). Ten patients (18%) had Trisomy 21. IBD was diagnosed after age 5 in 63% (n = 34). IBD presentation consisted of colonic or small bowel inflammation resembling IBD in 69% (n = 38), unexplained or persistent fistula in 18% (n = 10) and unexplained HAEC >5 years old or unresponsive to standard treatment in 13% (n = 7). Biological agents were the most effective (80%) medications. A third of patients required a surgical procedure for IBD.ConclusionMore than half of the patients were diagnosed with HD-IBD after 5 years old. Long segment disease, HAEC after pull through operation and trisomy 21 may represent risk factors for this condition. Investigation for possible IBD should be considered in children with unexplained fistulae, HAEC beyond the age of 5 or unresponsive to standard therapy, and symptoms suggestive of IBD. Biological agents were the most effective medical treatment.Level of EvidenceLevel 4 相似文献
9.
10.